A Long-term Safety Study of Once-daily Travatan
Overview
Long term safety study of TRAVATAN in patients with Open-angle glaucoma or ocular hypertension.
Full Title of Study: “A Long-term Safety Study of Once-daily TRAVATAN”
Study Type
- Study Type: Interventional
- Study Design
- Allocation: Non-Randomized
- Intervention Model: Single Group Assignment
- Primary Purpose: Treatment
- Masking: None (Open Label)
- Study Primary Completion Date: March 2009
Interventions
- Drug: Travatan
- Travoprost (0.004%) 1 drop each eye once daily
Arms, Groups and Cohorts
- Experimental: Travatan
- Travoprost (0.004%)
Clinical Trial Outcome Measures
Primary Measures
- Mean Intraocular Pressure
- Time Frame: At 5 years.
- Mean IOP for the patient’s worse eye at baseline was used in the secondary endpoint analysis. 2 consecutive IOP measurements for each eye were taken. If the 2 measurements for the same eye differ by 4 mmHg or less, the average of the measurements would be considered as the mean IOP for that eye. If the 2 measurements for the same eye differ by more than 4 mmHg, then a third measurement was to be taken. All IOP measurements were performed with a Goldmann applanation tonometer.
Participating in This Clinical Trial
Adult patients of any race and either sex with chronic angle-closure glaucoma.
Gender Eligibility: All
Minimum Age: 18 Years
Maximum Age: N/A
Are Healthy Volunteers Accepted: No
Investigator Details
- Lead Sponsor
- Alcon Research
- Provider of Information About this Clinical Study
- Sponsor
Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.